Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567710 · ClinicalTrials.gov registry record · Phase 2
A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study
A Phase 2 study, sponsored by BioLineRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
NCT00567710: Completed Phase 2 study, sponsored by BioLineRx.
NCT00567710 is a Phase 2 study that has completed, run by BioLineRx. The registered enrollment target is 360 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (171% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00567710, a Phase 2 study, has completed, sponsored by BioLineRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
Study Summary
This is a prospective, six-week, randomized, double blind, placebo-controlled, multi-center study in patients with schizophrenia who are experiencing an acute exacerbation of psychosis.
Interventions
- DRUG Placebo
- DRUG Risperidone
- DRUG BL - 1020
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
What the finished NCT00567710 record still lists
NCT00567710 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (171% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00567710 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00567710 about?
NCT00567710 is a clinical study titled "A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study". This is a prospective, six-week, randomized, double blind, placebo-controlled, multi-center study in patients with schizophrenia who are experiencing an acute exacerbation of psychosis.
What is the current status of trial NCT00567710?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2008-07. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00567710?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), BL - 1020 (DRUG).
Who is sponsoring clinical trial NCT00567710?
This trial is sponsored by BioLineRx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00567710's enrollment target sits among peer trials
360 123rd of 2000 higher than 1,874 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia